Matt’s Take

Matt's Take Matthew Herper

Can we really get better Covid vaccines? There are big hurdles, but some hope

Matt's Take Matthew Herper

New Covid trial results may point toward better ways to study medicines

Matt's Take Matthew Herper

Gilead’s Dan O’Day is pharma’s most charming executive — but with his deals falling apart, charm may not be enough

Matt's Take Matthew Herper

The fall of Eric Lander and the end of science’s ‘big ego’ era

Matt's Take Matthew Herper

Biden’s plan to end policy of keeping Covid vaccine doses in reserve is the first step in a difficult journey

Matt's Take Matthew Herper

Antibody drugs seem to work. But the virus is moving faster than we can make them

Matt's Take Matthew Herper

Eager for a Covid vaccine, Trump now trusts drug companies he previously vilified

Matt's Take Matthew Herper

The U.S. gets a D- in the coronavirus fight. That stands for ‘disorganization,’ and it’s fixable

Matt's Take Matthew Herper

Coronavirus testing is starting to get better — but it has a long way to go

Matt's Take Matthew Herper

Why Trump’s coronavirus speech, designed to calm, deepened panic

Matt's Take Matthew Herper

The coronavirus exposes our health care system’s weaknesses. We can be stronger

Biotech Adam Feuerstein and Matthew Herper

STAT’s guide to the most important, beneficial drugs approved in the past decade

Matt's Take Matthew Herper

The debate over America’s drug-pricing system is built on myths. It’s time to face reality